Amneal Wins Race For US NuvaRing Rival
Immediately Started Commercialization Of Contraceptive
Executive Summary
Amneal has become the first company to secure US approval for, and to launch, a generic alternative to Merck & Co’s top-selling, off-patent NuvaRing contraceptive device in the US. Other generics developers appear to be several months behind.
You may also be interested in...
Three Not A Magic Number For Mayne With Another NuvaRing CRL
Australia’s Mayne Pharma has announced another complete response letter for its proposed generic version of Organon’s NuvaRing (etonogestrel/ethinylestradiol) contraceptive device, marking a trio of setbacks for the ANDA product.
Estetrol Approvals Mark 'Turning Point' For Mithra
Recent Canadian, European and US endorsements of Mithra’s estetrol-based Estelle novel oral contraceptive mark a “turning point” for the Belgian firm, which has also seen success with its Myring generic rival to NuvaRing for which it expects to see further launches this year.
Amneal Completes Kashiv Takeover
Amneal says it has taken the latest step towards “Amneal 2.0” after completing its deal to acquire Kashiv Specialty Pharmaceuticals.